Michelle Robertson Sells 1,568 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) Stock
Editas Medicine, Inc. (NASDAQ:EDIT) CFO Michelle Robertson sold 1,568 shares of the company’s stock in a transaction dated Tuesday, January 12th. The shares were sold at an average price of $78.27, for a total transaction of $122,727.36. Following the sale, the chief financial officer now directly owns 18,432 shares of the company’s stock, valued at approximately $1,442,672.64. The sale was disclosed in a filing with the SEC, which is available at this link.
Shares of EDIT stock opened at $73.30 on Thursday. The firm’s 50 day moving average price is $62.63 and its 200-day moving average price is $39.43. Editas Medicine, Inc. has a one year low of $14.01 and a one year high of $99.95. The firm has a market cap of $4.57 billion, a P/E ratio of -42.13 and a beta of 1.83.
Editas Medicine (NASDAQ:EDIT) last released its earnings results on Thursday, November 5th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.66) by $0.78. The company had revenue of $62.84 million for the quarter, compared to analyst estimates of $6.36 million. Editas Medicine had a negative net margin of 99.62% and a negative return on equity of 26.74%. The firm’s quarterly revenue was up 1532.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.66) EPS. Analysts forecast that Editas Medicine, Inc. will post -1.78 EPS for the current fiscal year.
EDIT has been the subject of several research reports. Raymond James cut shares of Editas Medicine from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 7th. Morgan Stanley increased their price target on shares of Editas Medicine from $30.00 to $64.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 16th. Wells Fargo & Company increased their price target on shares of Editas Medicine from $69.00 to $86.00 and gave the company an “overweight” rating in a research note on Wednesday. Robert W. Baird initiated coverage on shares of Editas Medicine in a research note on Monday, November 2nd. They issued an “underperform” rating and a $14.00 price target for the company. Finally, BidaskClub raised shares of Editas Medicine from a “buy” rating to a “strong-buy” rating in a research note on Friday, December 18th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Editas Medicine has an average rating of “Hold” and an average target price of $50.43.
About Editas Medicine
Editas Medicine, Inc operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas.
Featured Article: How a Back-End Load Mutual Fund Works
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.